These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19955045)

  • 1. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Kvamme MK; Kristiansen IS; Lie E; Kvien TK
    J Rheumatol; 2010 Jan; 37(1):26-31. PubMed ID: 19955045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry.
    Buitinga L; Braakman-Jansen LM; Taal E; Kievit W; Visser H; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):826-32. PubMed ID: 22262513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
    J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
    J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
    Tubach F; Pham T; Skomsvoll JF; Mikkelsen K; Bjørneboe O; Ravaud P; Dougados M; Kvien TK
    Arthritis Rheum; 2006 Dec; 55(6):960-3. PubMed ID: 17139643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation.
    Teng YK; Verburg RJ; Sont JK; van den Hout WB; Breedveld FC; van Laar JM
    Arthritis Rheum; 2005 Aug; 52(8):2272-6. PubMed ID: 16052541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study.
    Tubach F; Ravaud P; Martin-Mola E; Awada H; Bellamy N; Bombardier C; Felson DT; Hajjaj-Hassouni N; Hochberg M; Logeart I; Matucci-Cerinic M; van de Laar M; van der Heijde D; Dougados M
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1699-707. PubMed ID: 22674853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis.
    Maksymowych WP; Richardson R; Mallon C; van der Heijde D; Boonen A
    Arthritis Rheum; 2007 Feb; 57(1):133-9. PubMed ID: 17266072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
    van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A;
    Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
    Lillegraven S; Kristiansen IS; Kvien TK
    Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey.
    Brodszky V; Péntek M; Bálint PV; Géher P; Hajdu O; Hodinka L; Horváth G; Koó E; Polgár A; Seszták M; Szántó S; Ujfalussy I; Gulácsi L
    Scand J Rheumatol; 2010 Aug; 39(4):303-9. PubMed ID: 20166848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
    Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
    Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
    Petrou S; Hockley C
    Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
    Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
    Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
    J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales.
    Kwok T; Pope JE
    J Rheumatol; 2010 May; 37(5):1024-8. PubMed ID: 20231193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.